title: [Vinpotropil in the treatment of dyscirculatory encephalopathy with cognitive impairment without dementia].
abstract: The fixed combination containing 5 mg of vinpocetine and 400 mg of pyracetam (vinpotropil) was prescribed to 349 patients with dyscirculatory encephalopathy, I-II stages in dose one capsule three times a day during 3 months. After this treatment, repeated neuropsychological testing showed significant diminishing of dysexecutive cognitive impairment linked with frontal lobes dysfunction. The cognitive improvement was associated with the regress of subjective neurological symptoms like headache, dizziness, tinnitus, fatigue and insomnia. Vinpotropil was safe and well tolerated in elderly patients with chronic cerebral vascular insufficiency.
authors.forename: V V
authors.initials: VV
authors.lastname: Zakharov
mesh_terms: D000328:Adult; D000368:Aged; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D015140:Dementia, Vascular / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004244:Dizziness / Q000503:physiopathology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005221:Fatigue / Q000503:physiopathology; D005260:Female; D005625:Frontal Lobe / Q000187:drug effects / Q000503:physiopathology; D006261:Headache / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010889:Piracetam / Q000008:administration & dosage* / Q000009:adverse effects; D007319:Sleep Initiation and Maintenance Disorders / Q000503:physiopathology; D014012:Tinnitus / Q000503:physiopathology; D016896:Treatment Outcome; D014748:Vinca Alkaloids / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D004338:Drug Combinations; D014748:Vinca Alkaloids; C532690:piracetam, vinpocetine drug combination; D010889:Piracetam